<?xml version='1.0' encoding='utf-8'?>
<svg xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" id="chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa" class="pygal-chart" viewBox="0 0 800 1000"><!--Generated with pygal 2.4.0 (lxml) Â©Kozea 2012-2016 on 2019-02-08--><!--http://pygal.org--><!--http://github.com/Kozea/pygal--><defs><style type="text/css">#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa{-webkit-user-select:none;-webkit-font-smoothing:antialiased;font-family:Consolas,"Liberation Mono",Menlo,Courier,monospace}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .title{font-family:Consolas,"Liberation Mono",Menlo,Courier,monospace;font-size:16px}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .legends .legend text{font-family:Consolas,"Liberation Mono",Menlo,Courier,monospace;font-size:14px}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .axis text{font-family:Consolas,"Liberation Mono",Menlo,Courier,monospace;font-size:10px}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .axis text.major{font-family:Consolas,"Liberation Mono",Menlo,Courier,monospace;font-size:10px}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .text-overlay text.value{font-family:Consolas,"Liberation Mono",Menlo,Courier,monospace;font-size:16px}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .text-overlay text.label{font-family:Consolas,"Liberation Mono",Menlo,Courier,monospace;font-size:10px}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .tooltip{font-family:Consolas,"Liberation Mono",Menlo,Courier,monospace;font-size:14px}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa text.no_data{font-family:Consolas,"Liberation Mono",Menlo,Courier,monospace;font-size:64px}
#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa{background-color:transparent}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa path,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa line,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa rect,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa circle{-webkit-transition:400ms ease-in;-moz-transition:400ms ease-in;transition:400ms ease-in}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .graph &gt; .background{fill:transparent}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .plot &gt; .background{fill:transparent}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .graph{fill:rgba(0,0,0,.87)}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa text.no_data{fill:rgba(0,0,0,1)}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .title{fill:rgba(0,0,0,1)}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .legends .legend text{fill:rgba(0,0,0,.87)}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .legends .legend:hover text{fill:rgba(0,0,0,1)}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .axis .line{stroke:rgba(0,0,0,1)}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .axis .guide.line{stroke:rgba(0,0,0,.54)}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .axis .major.line{stroke:rgba(0,0,0,.87)}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .axis text.major{fill:rgba(0,0,0,1)}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .axis.y .guides:hover .guide.line,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .line-graph .axis.x .guides:hover .guide.line,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .stackedline-graph .axis.x .guides:hover .guide.line,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .xy-graph .axis.x .guides:hover .guide.line{stroke:rgba(0,0,0,1)}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .axis .guides:hover text{fill:rgba(0,0,0,1)}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .reactive{fill-opacity:.4;stroke-opacity:.8}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .ci{stroke:rgba(0,0,0,.87)}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .reactive.active,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .active .reactive{fill-opacity:.5;stroke-opacity:.9;stroke-width:4}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .ci .reactive.active{stroke-width:1.5}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .series text{fill:rgba(0,0,0,1)}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .tooltip rect{fill:transparent;stroke:rgba(0,0,0,1);-webkit-transition:opacity 400ms ease-in;-moz-transition:opacity 400ms ease-in;transition:opacity 400ms ease-in}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .tooltip .label{fill:rgba(0,0,0,.87)}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .tooltip .label{fill:rgba(0,0,0,.87)}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .tooltip .legend{font-size:.8em;fill:rgba(0,0,0,.54)}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .tooltip .x_label{font-size:.6em;fill:rgba(0,0,0,1)}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .tooltip .xlink{font-size:.5em;text-decoration:underline}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .tooltip .value{font-size:1.5em}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .bound{font-size:.5em}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .max-value{font-size:.75em;fill:rgba(0,0,0,.54)}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .map-element{fill:transparent;stroke:rgba(0,0,0,.54) !important}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .map-element .reactive{fill-opacity:inherit;stroke-opacity:inherit}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-0,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-0 a:visited{stroke:#0000ff;fill:#0000ff}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-1,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-1 a:visited{stroke:#3d46ff;fill:#3d46ff}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-2,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-2 a:visited{stroke:#506eff;fill:#506eff}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-3,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-3 a:visited{stroke:#5794ff;fill:#5794ff}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-4,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-4 a:visited{stroke:#55b8ff;fill:#55b8ff}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-5,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-5 a:visited{stroke:#44ddff;fill:#44ddff}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-6,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-6 a:visited{stroke:#08fdfb;fill:#08fdfb}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-7,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-7 a:visited{stroke:#29e6d1;fill:#29e6d1}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-8,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-8 a:visited{stroke:#31d0a8;fill:#31d0a8}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-9,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-9 a:visited{stroke:#30bb81;fill:#30bb81}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-10,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-10 a:visited{stroke:#29a559;fill:#29a559}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-11,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-11 a:visited{stroke:#1a9131;fill:#1a9131}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-12,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-12 a:visited{stroke:#158400;fill:#158400}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-13,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-13 a:visited{stroke:#4b9900;fill:#4b9900}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-14,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-14 a:visited{stroke:#73ae00;fill:#73ae00}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-15,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-15 a:visited{stroke:#99c300;fill:#99c300}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-16,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-16 a:visited{stroke:#bed900;fill:#bed900}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-17,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-17 a:visited{stroke:#e3ef00;fill:#e3ef00}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-18,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-18 a:visited{stroke:#fff700;fill:#fff700}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-19,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-19 a:visited{stroke:#ffd800;fill:#ffd800}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-20,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-20 a:visited{stroke:#ffb900;fill:#ffb900}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-21,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .color-21 a:visited{stroke:#ff9800;fill:#ff9800}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .text-overlay .color-0 text{fill:black}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .text-overlay .color-1 text{fill:black}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .text-overlay .color-2 text{fill:black}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .text-overlay .color-3 text{fill:black}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .text-overlay .color-4 text{fill:black}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .text-overlay .color-5 text{fill:black}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .text-overlay .color-6 text{fill:black}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .text-overlay .color-7 text{fill:black}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .text-overlay .color-8 text{fill:black}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .text-overlay .color-9 text{fill:black}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .text-overlay .color-10 text{fill:black}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .text-overlay .color-11 text{fill:black}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .text-overlay .color-12 text{fill:black}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .text-overlay .color-13 text{fill:black}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .text-overlay .color-14 text{fill:black}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .text-overlay .color-15 text{fill:black}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .text-overlay .color-16 text{fill:black}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .text-overlay .color-17 text{fill:black}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .text-overlay .color-18 text{fill:black}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .text-overlay .color-19 text{fill:black}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .text-overlay .color-20 text{fill:black}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .text-overlay .color-21 text{fill:black}
#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa text.no_data{text-anchor:middle}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .guide.line{fill:none}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .centered{text-anchor:middle}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .title{text-anchor:middle}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .legends .legend text{fill-opacity:1}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .axis.x text{text-anchor:middle}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .axis.x:not(.web) text[transform]{text-anchor:start}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .axis.x:not(.web) text[transform].backwards{text-anchor:end}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .axis.y text{text-anchor:end}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .axis.y text[transform].backwards{text-anchor:start}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .axis.y2 text{text-anchor:start}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .axis.y2 text[transform].backwards{text-anchor:end}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .axis .guide.line{stroke-dasharray:4,4}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .axis .major.guide.line{stroke-dasharray:6,6}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .horizontal .axis.y .guide.line,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .horizontal .axis.y2 .guide.line,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .vertical .axis.x .guide.line{opacity:0}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .horizontal .axis.always_show .guide.line,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .vertical .axis.always_show .guide.line{opacity:1 !important}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .axis.y .guides:hover .guide.line,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .axis.y2 .guides:hover .guide.line,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .axis.x .guides:hover .guide.line{opacity:1}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .axis .guides:hover text{opacity:1}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .nofill{fill:none}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .subtle-fill{fill-opacity:.2}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .dot{stroke-width:1px;fill-opacity:1}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .dot.active{stroke-width:5px}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .dot.negative{fill:transparent}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa text,#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa tspan{stroke:none !important}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .series text.active{opacity:1}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .tooltip rect{fill-opacity:.95;stroke-width:.5}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .tooltip text{fill-opacity:1}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .showable{visibility:hidden}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .showable.shown{visibility:visible}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .gauge-background{fill:rgba(229,229,229,1);stroke:none}#chart-f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa .bg-lines{stroke:transparent;stroke-width:2px}</style><script type="text/javascript">window.pygal = window.pygal || {};window.pygal.config = window.pygal.config || {};window.pygal.config['f9b53a2a-9c9c-4fd0-9ba5-0b210bece5aa'] = {"dynamic_print_values": false, "truncate_label": null, "inner_radius": 0, "print_values": false, "xrange": null, "box_mode": "extremes", "legend_at_bottom_columns": null, "height": 1000, "legend_at_bottom": false, "show_legend": false, "show_dots": true, "explicit_size": false, "y_labels_major": null, "show_minor_x_labels": true, "width": 800, "force_uri_protocol": "https", "half_pie": false, "style": {"major_label_font_family": "Consolas, \"Liberation Mono\", Menlo, Courier, monospace", "title_font_family": "Consolas, \"Liberation Mono\", Menlo, Courier, monospace", "stroke_opacity": ".8", "legend_font_family": "Consolas, \"Liberation Mono\", Menlo, Courier, monospace", "colors": ["#0000ff", "#3d46ff", "#506eff", "#5794ff", "#55b8ff", "#44ddff", "#08fdfb", "#29e6d1", "#31d0a8", "#30bb81", "#29a559", "#1a9131", "#158400", "#4b9900", "#73ae00", "#99c300", "#bed900", "#e3ef00", "#fff700", "#ffd800", "#ffb900", "#ff9800", "#ff7300", "#ff4500"], "legend_font_size": 14, "no_data_font_family": "Consolas, \"Liberation Mono\", Menlo, Courier, monospace", "major_label_font_size": 10, "value_background": "rgba(229, 229, 229, 1)", "ci_colors": [], "label_font_family": "Consolas, \"Liberation Mono\", Menlo, Courier, monospace", "label_font_size": 10, "tooltip_font_size": 14, "value_font_size": 16, "font_family": "Consolas, \"Liberation Mono\", Menlo, Courier, monospace", "opacity": ".4", "foreground": "rgba(0, 0, 0, .87)", "plot_background": "transparent", "value_label_font_size": 10, "value_label_font_family": "Consolas, \"Liberation Mono\", Menlo, Courier, monospace", "background": "transparent", "no_data_font_size": 64, "value_colors": [], "guide_stroke_dasharray": "4,4", "transition": "400ms ease-in", "foreground_subtle": "rgba(0, 0, 0, .54)", "value_font_family": "Consolas, \"Liberation Mono\", Menlo, Courier, monospace", "tooltip_font_family": "Consolas, \"Liberation Mono\", Menlo, Courier, monospace", "title_font_size": 16, "stroke_opacity_hover": ".9", "major_guide_stroke_dasharray": "6,6", "opacity_hover": ".5", "foreground_strong": "rgba(0, 0, 0, 1)"}, "x_label_rotation": 0, "fill": false, "missing_value_fill_truncation": "x", "zero": 0, "margin_right": null, "interpolation_parameters": {}, "x_labels_major": null, "rounded_bars": null, "show_y_labels": true, "dots_size": 2.5, "show_y_guides": false, "show_minor_y_labels": true, "x_labels": null, "y_title": null, "order_min": null, "formatter": null, "disable_xml_declaration": false, "strict": false, "css": ["file://style.css", "file://graph.css"], "tooltip_fancy_mode": true, "defs": [], "show_only_major_dots": false, "y_label_rotation": 0, "show_x_labels": true, "min_scale": 4, "show_x_guides": true, "spacing": 1, "x_labels_major_count": null, "pretty_print": false, "tooltip_border_radius": 0, "interpolate": null, "js": ["//kozea.github.io/pygal.js/2.0.x/pygal-tooltips.min.js"], "y_labels": null, "stroke_style": null, "title": null, "print_labels": false, "interpolation_precision": 250, "x_title": null, "y_labels_major_every": null, "logarithmic": false, "legends": ["NCT03549442", "NCT03464916", "NCT02794246", "NCT02546167", "NCT03502577", "NCT03070327", "NCT03710421", "NCT03338972", "NCT03672318", "NCT03448978", "NCT03602612", "NCT03288493", "NCT02215967", "NCT03651128", "NCT03548207", "NCT03318861", "NCT03601078", "NCT03274219", "NCT03361748", "NCT03430011", "NCT02658929", "NCT02529813"], "max_scale": 16, "print_zeroes": true, "no_data_text": "No data", "truncate_legend": null, "x_labels_major_every": null, "secondary_range": null, "legend_box_size": 12, "no_prefix": false, "stroke": true, "stack_from_top": false, "include_x_axis": false, "range": null, "classes": ["pygal-chart"], "margin_top": null, "margin_left": null, "y_labels_major_count": null, "margin_bottom": null, "inverse_y_axis": false, "margin": 20, "allow_interruptions": false, "print_values_position": "center"}</script><script type="text/javascript" xlink:href="https://kozea.github.io/pygal.js/2.0.x/pygal-tooltips.min.js"/></defs><title>Pygal</title><g class="graph horizontalbar-graph horizontal"><rect class="background" height="1000" width="800" x="0" y="0"/><g class="plot" transform="translate(20, 20)"><rect class="background" height="949" width="760" x="0" y="0"/><g class="axis x always_show"><g class="guides"><path class="axis major line" d="M14.615385 0.000000 v949.000000"/><text class="major" x="14.6153846154" y="964.0">0</text></g><g class="guides"><path class="guide line" d="M75.512821 0.000000 v949.000000"/><text class="" x="75.5128205128" y="964.0">1</text></g><g class="guides"><path class="guide line" d="M136.410256 0.000000 v949.000000"/><text class="" x="136.41025641" y="964.0">2</text></g><g class="guides"><path class="guide line" d="M197.307692 0.000000 v949.000000"/><text class="" x="197.307692308" y="964.0">3</text></g><g class="guides"><path class="guide line" d="M258.205128 0.000000 v949.000000"/><text class="" x="258.205128205" y="964.0">4</text></g><g class="guides"><path class="major guide line" d="M319.102564 0.000000 v949.000000"/><text class="major" x="319.102564103" y="964.0">5</text></g><g class="guides"><path class="guide line" d="M380.000000 0.000000 v949.000000"/><text class="" x="380.0" y="964.0">6</text></g><g class="guides"><path class="guide line" d="M440.897436 0.000000 v949.000000"/><text class="" x="440.897435897" y="964.0">7</text></g><g class="guides"><path class="guide line" d="M501.794872 0.000000 v949.000000"/><text class="" x="501.794871795" y="964.0">8</text></g><g class="guides"><path class="guide line" d="M562.692308 0.000000 v949.000000"/><text class="" x="562.692307692" y="964.0">9</text></g><g class="guides"><path class="major guide line" d="M623.589744 0.000000 v949.000000"/><text class="major" x="623.58974359" y="964.0">10</text></g><g class="guides"><path class="guide line" d="M684.487179 0.000000 v949.000000"/><text class="" x="684.487179487" y="964.0">11</text></g><g class="guides"><path class="guide line" d="M745.384615 0.000000 v949.000000"/><text class="" x="745.384615385" y="964.0">12</text></g></g><g class="series serie-21 color-21"><g class="bars"><g class="bar"><desc class="label">CD19+ CAR T Cells for Lymphoid Malignancies</desc><rect class="rect reactive tooltip-trigger" height="32.12" rx="0" ry="0" width="60.8974358974" x="14.6153846154" y="841.69"/><desc class="value">1</desc><desc class="x centered">45.0641025641</desc><desc class="y centered">857.75</desc></g></g></g><g class="series serie-20 color-20"><g class="bars"><g class="bar"><desc class="label">Study of bb2121 in Multiple Myeloma</desc><rect class="rect reactive tooltip-trigger" height="32.12" rx="0" ry="0" width="487.179487179" x="14.6153846154" y="805.19"/><desc class="value">8</desc><desc class="x centered">258.205128205</desc><desc class="y centered">821.25</desc></g></g></g><g class="series serie-19 color-19"><g class="bars"><g class="bar"><desc class="label">Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma</desc><rect class="rect reactive tooltip-trigger" height="32.12" rx="0" ry="0" width="548.076923077" x="14.6153846154" y="768.69"/><desc class="value">9</desc><desc class="x centered">288.653846154</desc><desc class="y centered">784.75</desc></g></g></g><g class="series serie-18 color-18"><g class="bars"><g class="bar"><desc class="label">Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa)</desc><rect class="rect reactive tooltip-trigger" height="32.12" rx="0" ry="0" width="487.179487179" x="14.6153846154" y="732.19"/><desc class="value">8</desc><desc class="x centered">258.205128205</desc><desc class="y centered">748.25</desc></g></g></g><g class="series serie-17 color-17"><g class="bars"><g class="bar"><desc class="label">Study of bb21217 in Multiple Myeloma</desc><rect class="rect reactive tooltip-trigger" height="32.12" rx="0" ry="0" width="487.179487179" x="14.6153846154" y="695.69"/><desc class="value">8</desc><desc class="x centered">258.205128205</desc><desc class="y centered">711.75</desc></g></g></g><g class="series serie-16 color-16"><g class="bars"><g class="bar"><desc class="label">An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma</desc><rect class="rect reactive tooltip-trigger" height="32.12" rx="0" ry="0" width="182.692307692" x="14.6153846154" y="659.19"/><desc class="value">3</desc><desc class="x centered">105.961538462</desc><desc class="y centered">675.25</desc></g></g></g><g class="series serie-15 color-15"><g class="bars"><g class="bar"><desc class="label">A Study Evaluating the Safety and Efficacy of KITE-585 in Subjects With Relapsed/Refractory Multiple Myeloma</desc><rect class="rect reactive tooltip-trigger" height="32.12" rx="0" ry="0" width="608.974358974" x="14.6153846154" y="622.69"/><desc class="value">10</desc><desc class="x centered">319.102564103</desc><desc class="y centered">638.75</desc></g></g></g><g class="series serie-14 color-14"><g class="bars"><g class="bar"><desc class="label">A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma</desc><rect class="rect reactive tooltip-trigger" height="32.12" rx="0" ry="0" width="730.769230769" x="14.6153846154" y="586.19"/><desc class="value">12</desc><desc class="x centered">380.0</desc><desc class="y centered">602.25</desc></g></g></g><g class="series serie-13 color-13"><g class="bars"><g class="bar"><desc class="label">Efficacy and Safety Study of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)</desc><rect class="rect reactive tooltip-trigger" height="32.12" rx="0" ry="0" width="60.8974358974" x="14.6153846154" y="549.69"/><desc class="value">1</desc><desc class="x centered">45.0641025641</desc><desc class="y centered">565.75</desc></g></g></g><g class="series serie-12 color-12"><g class="bars"><g class="bar"><desc class="label">Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma</desc><rect class="rect reactive tooltip-trigger" height="32.12" rx="0" ry="0" width="60.8974358974" x="14.6153846154" y="513.19"/><desc class="value">1</desc><desc class="x centered">45.0641025641</desc><desc class="y centered">529.25</desc></g></g></g><g class="series serie-11 color-11"><g class="bars"><g class="bar"><desc class="label">P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)</desc><rect class="rect reactive tooltip-trigger" height="32.12" rx="0" ry="0" width="365.384615385" x="14.6153846154" y="476.69"/><desc class="value">6</desc><desc class="x centered">197.307692308</desc><desc class="y centered">492.75</desc></g></g></g><g class="series serie-10 color-10"><g class="bars"><g class="bar"><desc class="label">T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma</desc><rect class="rect reactive tooltip-trigger" height="32.12" rx="0" ry="0" width="60.8974358974" x="14.6153846154" y="440.19"/><desc class="value">1</desc><desc class="x centered">45.0641025641</desc><desc class="y centered">456.25</desc></g></g></g><g class="series serie-9 color-9"><g class="bars"><g class="bar"><desc class="label">Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma</desc><rect class="rect reactive tooltip-trigger" height="32.12" rx="0" ry="0" width="182.692307692" x="14.6153846154" y="403.69"/><desc class="value">3</desc><desc class="x centered">105.961538462</desc><desc class="y centered">419.75</desc></g></g></g><g class="series serie-8 color-8"><g class="bars"><g class="bar"><desc class="label">Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma</desc><rect class="rect reactive tooltip-trigger" height="32.12" rx="0" ry="0" width="60.8974358974" x="14.6153846154" y="367.19"/><desc class="value">1</desc><desc class="x centered">45.0641025641</desc><desc class="y centered">383.25</desc></g></g></g><g class="series serie-7 color-7"><g class="bars"><g class="bar"><desc class="label">Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma</desc><rect class="rect reactive tooltip-trigger" height="32.12" rx="0" ry="0" width="60.8974358974" x="14.6153846154" y="330.69"/><desc class="value">1</desc><desc class="x centered">45.0641025641</desc><desc class="y centered">346.75</desc></g></g></g><g class="series serie-6 color-6"><g class="bars"><g class="bar"><desc class="label">CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory Multiple Myeloma</desc><rect class="rect reactive tooltip-trigger" height="32.12" rx="0" ry="0" width="60.8974358974" x="14.6153846154" y="294.19"/><desc class="value">1</desc><desc class="x centered">45.0641025641</desc><desc class="y centered">310.25</desc></g></g></g><g class="series serie-5 color-5"><g class="bars"><g class="bar"><desc class="label">BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma</desc><rect class="rect reactive tooltip-trigger" height="32.12" rx="0" ry="0" width="60.8974358974" x="14.6153846154" y="257.69"/><desc class="value">1</desc><desc class="x centered">45.0641025641</desc><desc class="y centered">273.75</desc></g></g></g><g class="series serie-4 color-4"><g class="bars"><g class="bar"><desc class="label">BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (LY3039478) to Treat Relapsed or Persistent Multiple Myeloma</desc><rect class="rect reactive tooltip-trigger" height="32.12" rx="0" ry="0" width="60.8974358974" x="14.6153846154" y="221.19"/><desc class="value">1</desc><desc class="x centered">45.0641025641</desc><desc class="y centered">237.25</desc></g></g></g><g class="series serie-3 color-3"><g class="bars"><g class="bar"><desc class="label">CART-BCMA Cells for Multiple Myeloma</desc><rect class="rect reactive tooltip-trigger" height="32.12" rx="0" ry="0" width="60.8974358974" x="14.6153846154" y="184.69"/><desc class="value">1</desc><desc class="x centered">45.0641025641</desc><desc class="y centered">200.75</desc></g></g></g><g class="series serie-2 color-2"><g class="bars"><g class="bar"><desc class="label">CART-19 Post-ASCT for Multiple Myeloma</desc><rect class="rect reactive tooltip-trigger" height="32.12" rx="0" ry="0" width="60.8974358974" x="14.6153846154" y="148.19"/><desc class="value">1</desc><desc class="x centered">45.0641025641</desc><desc class="y centered">164.25</desc></g></g></g><g class="series serie-1 color-1"><g class="bars"><g class="bar"><desc class="label">Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients</desc><rect class="rect reactive tooltip-trigger" height="32.12" rx="0" ry="0" width="121.794871795" x="14.6153846154" y="111.69"/><desc class="value">2</desc><desc class="x centered">75.5128205128</desc><desc class="y centered">127.75</desc></g></g></g><g class="series serie-0 color-0"><g class="bars"><g class="bar"><desc class="label">Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma</desc><rect class="rect reactive tooltip-trigger" height="32.12" rx="0" ry="0" width="60.8974358974" x="14.6153846154" y="75.19"/><desc class="value">1</desc><desc class="x centered">45.0641025641</desc><desc class="y centered">91.25</desc></g></g></g></g><g class="titles"/><g class="plot overlay" transform="translate(20, 20)"><g class="series serie-21 color-21"/><g class="series serie-20 color-20"/><g class="series serie-19 color-19"/><g class="series serie-18 color-18"/><g class="series serie-17 color-17"/><g class="series serie-16 color-16"/><g class="series serie-15 color-15"/><g class="series serie-14 color-14"/><g class="series serie-13 color-13"/><g class="series serie-12 color-12"/><g class="series serie-11 color-11"/><g class="series serie-10 color-10"/><g class="series serie-9 color-9"/><g class="series serie-8 color-8"/><g class="series serie-7 color-7"/><g class="series serie-6 color-6"/><g class="series serie-5 color-5"/><g class="series serie-4 color-4"/><g class="series serie-3 color-3"/><g class="series serie-2 color-2"/><g class="series serie-1 color-1"/><g class="series serie-0 color-0"/></g><g class="plot text-overlay" transform="translate(20, 20)"><g class="series serie-21 color-21"/><g class="series serie-20 color-20"/><g class="series serie-19 color-19"/><g class="series serie-18 color-18"/><g class="series serie-17 color-17"/><g class="series serie-16 color-16"/><g class="series serie-15 color-15"/><g class="series serie-14 color-14"/><g class="series serie-13 color-13"/><g class="series serie-12 color-12"/><g class="series serie-11 color-11"/><g class="series serie-10 color-10"/><g class="series serie-9 color-9"/><g class="series serie-8 color-8"/><g class="series serie-7 color-7"/><g class="series serie-6 color-6"/><g class="series serie-5 color-5"/><g class="series serie-4 color-4"/><g class="series serie-3 color-3"/><g class="series serie-2 color-2"/><g class="series serie-1 color-1"/><g class="series serie-0 color-0"/></g><g class="plot tooltip-overlay" transform="translate(20, 20)"><g class="tooltip" style="opacity: 0" transform="translate(0 0)"><rect class="tooltip-box" height="0" rx="0" ry="0" width="0"/><g class="text"/></g></g></g></svg>